Economic Observation Network Yinnuo Pharmar-B (02591) saw a 38.57% increase in revenue in the first half of 2026, with a decline in gross profit margin and a loss of 115 million yuan in net profit attributable to the parent company

Company fundamentals:
In the first half of 2026, the revenue was 78.218 million yuan, a year-on-year increase of 38.57%, but the net profit attributable to the parent company still incurred a loss of 115 million yuan; More importantly, the gross profit margin has decreased from 89.4% in the same period last year to 72.45% Revenue growth and reduced losses were originally good things, but the significant decline in gross profit margin indicates that after the implementation of the medical insurance price reduction, "price for quantity" has been implemented, and profits have been compressed as the scale has increased. The market's patience for "when to make profits" is decreasing.

The above content is based on publicly available information and does not constitute investment advice.